trial

Tolerability of MDMA in Schizophrenia

NCTId NCT05770375
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 1, Phase 2 · Recruiting
Enrollment 20 (estimated)
Sponsored by Anya Bershad, MD, PhD
Primary completion 2027-03
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 1, Phase 2
Status
Recruiting
Enrollment
20 (estimated)
Study type
Interventional
Allocation
Na
Model
Single Group
Masking
None
Start
2025-04-01
Primary completion
2027-03
Eligibility
ALL · 18 Years · 60 Years

Interventions & indications

Drugs
MDMA 40mgMDMA 80mgMDMA 120mg

Sponsors

Anya Bershad, MD, PhDLead Sponsor
National Institutes of Health (NIH)Collaborator

Sites

1 total
Los Angeles, United States

Linked catalysts

1
Tolerability of MDMA in Schizophrenia — primary completion2027-03

Facts & assertions

4 sourced
Enrollment
20
Phase
PHASE1,PHASE2
Primary Completion Date
2027-03
Status
RECRUITING
relationships
The graph out of here
drug
MDMA 40mg
drug
MDMA 80mg
drug
MDMA 120mg
drug
lead_sponsor
Anya Bershad, MD, PhD
company
collaborator
National Institutes of Health (NIH)
company
indication
Schizophrenia
indication
Schizophrenia
indication